Valneva SE: Revenue from Chikungunya Vaccine has Nearly eightfold - Pipeline Offers Even More!
Valneva holds market-leading positions with its vaccines. I believe that together with Pfizer, a market leadership in Lyme disease vaccines is also possible!
Reading Time: 2 minutes
Among the speculative European biotechs, Valneva SE (i.) has distinguished itself as one of the leaders over the last month. The company already has approved vaccines against Chikungunya, Cholera, and Japanese Encephalitis (JE). The topic of Chikungunya has been particularly prominent in the media recently because the WHO has warned of a global Chikungunya epidemic after the disease spread in Asia. Furthermore, the European Medicines Agency (EMA) has lifted the temporary usage restrictions on the Chikungunya vaccine IXCHIQ for older individuals....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
